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Introduction
Metformin, a biguanide, has gained increasing
acceptance worldwide as an antidiabetic agent since
its introduction in 1957. Metformin predominantly
lowers glucose levels by reducing hepatic glucose 
output, while also increasing peripheral insulin sen-
sitivity, to some extent.1 In addition, metformin 
treatment is known to decrease macrovascular com-
plications of diabetes mellitus, as has previously been
reported in the well-known UK Prospective Diabetes
Study.2
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Background: Metformin is a worldwide accepted biguanide antidiabetic agent, and its effectiveness and benefit have
already been well established. Among the side effects of metformin, lactate acidosis is the most problematic because of
a high mortality rate, which impedes its use in clinical practice, especially in elderly patients with type 2 diabetes. Aging
is associated with a decreased renal function and increasing comorbidities, but few data are available regarding plasma
lactate levels in this unique population. In this study, we assessed fasting plasma lactate levels in ambulatory, elderly
Taiwanese patients with type 2 diabetes, who were taking the drug, metformin, to identify independent risk factors for
hyperlactemia in this group.
Methods: Sixty-six ambulatory type 2 diabetic patients, > 80 years of age (mean, 83.6 years; range, 80–90 years),
receiving metformin therapy, were enrolled, from January 2005 to September 2009, in the Diabetes Case Management
Program. A further 79 younger patients (also type 2 diabetics on metformin) served as controls (mean age, 59.9 years;
range, 37–79 years). Fasting serum electrolytes, creatinine, bicarbonate, glycated hemoglobin, plasma glucose and lac-
tate levels were determined.
Results: Lactate levels did not differ between the elderly and control groups (13.2 ± 5.2 mg/dL and 13.5 ± 4.8 mg/dL,
respectively). None of the patients fulfilled the lactic acidosis criteria. Patients in the elderly group had a significantly
lower daily metformin dose, higher creatinine levels, and lower estimated creatinine clearance, compared with the con-
trol group (all p < 0.05). Estimated creatinine clearance was negatively associated with lactate levels in the elderly group
(p < 0.05, r = −0.27), but not in the control group. Patients with fasting plasma glucose levels > 130 mg/dL had a 2.8-fold
increased risk of developing hyperlactemia.
Conclusion: Plasma lactate levels in ambulatory elderly patients with type 2 diabetes receiving metformin therapy did not
differ from those in a younger age group. Patients with fasting plasma glucose levels > 130 mg/dL had a 2.8-fold risk of
developing hyperlactemia, but none of them developed lactate acidosis. [J Chin Med Assoc 2010;73(12):617–622]
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Gastrointestinal tract discomfort is the most com-
mon adverse effect of metformin treatment, a phe-
nomenon which occurs in 5–30% of patients.3 Lactic
acidosis is a rare, but serious, metabolic consequence
of metformin therapy, and it has been found to be
associated with a mortality rate close to 50%.4 The inci-
dence of lactic acidosis has been reported to be
0.01–0.08 per 1,000 patient-years, which equates to
a 1-in-10 to 1-in-20 risk of phenformin-induced lactate
acidosis.5,6
Risk factors for the development of lactic acidosis
associated with metformin use, such as preexisting
cardiac disease, renal insufficiency, chronic pulmonary
disease with hypoxia, and congestive heart failure, are
typically considered to be contraindications for met-
formin therapy itself. Aging can be associated with
decreased renal function and increasing comorbidities.
There are little data available concerning the safety of
metformin in the treatment of elderly type 2 diabetic
patients. Misbin et al7 reported that 8 of 47 patients
(17%) with a confirmed diagnosis of lactic acidosis were
> 80 years of age 1 year after the Food and Drug
Administration approved metformin. The revised label
stated that metformin treatment should not be initiated
in patients ≥ 80 years of age.
This study aimed to assess fasting plasma lactate
levels in ambulatory elderly (≥ 80 years old) Taiwanese
patients with type 2 diabetes mellitus receiving various
doses of metformin, and to identify independent risk
factors associated with hyperlactemia in these patients.
Methods
Subjects
From January 2005 to September 2009, 66 elderly
(≥ 80 years old) metformin-treated patients with type 2
diabetes, in the Diabetes Case Management Program
of Taipei Veterans General Hospital, were enrolled 
in the study. In addition, 79 younger (< 80 years old)
metformin-treated patients with type 2 diabetes were
recruited to serve as the control group. The research
project was approved by the medical ethics committee
of Taipei Veterans General Hospital.
Demographics and blood sampling
Baseline information of body weight, body height,
body mass index (BMI) and medication was collected.
Overnight fasting blood samples were obtained from
all participants during scheduled diabetic outpatient
clinic visits for measurement of sodium, potassium,
chloride, creatinine, plasma glucose, glycated hemo-
globin (HbA1c), bicarbonate, and lactate levels.
Laboratory tests
The anion gap was determined using the equation
[sodium]-[chloride]-[bicarbonate] (mmol/L), while
estimated creatinine clearance rate (eCCr) was calcu-
lated using the Cockcroft and Gault equation.8 HbA1c
levels were measured by cation-exchange high-
performance liquid chromatography (Tosoh HLC-
723 G7; Tosoh Corp., Tokyo, Japan). Sodium, 
potassium, chloride, and lactate levels were deter-
mined using a Hitachi 7180 autoanalyzer (Hitachi
High-Technologies Corp., Tokyo, Japan). The refer-
ence range for fasting venous plasma lactate levels was
5.0–15.0 mg/dL.
Statistical analyses
Data are presented as mean ± standard deviation.
Categorical data were compared using the χ2 test, and
continuous data were compared using the Mann-
Whitney rank sum test. The associations between
variables and plasma lactate level were determined by
Pearson’s correlation test. Fasting plasma lactate levels
between patients in the 3 metformin dose groups
(≤ 1,000, 1,001–2,000 and > 2,000 mg/day) were
compared using the Kruskal-Wallis test. Univariate
predictors for hyperlactemia with a potential signifi-
cance (p < 0.2 in univariate analysis) were included in
the multivariate analysis. The odds ratio for hyper-
lactemia was calculated by multivariate logistic regres-
sion analysis. All statistical analyses were performed
using SPSS version 17 (SPSS Inc., Chicago, IL, USA)
for Windows. Differences were considered statistically
significant when p < 0.05.
Results
The basic characteristics of the 2 patient groups are
summarized in Table 1. Male patients outnumbered
female patients in both groups. Patients in the elderly
group had significantly lower daily metformin doses,
BMI and eCCr, and significantly higher creatinine
levels, compared with the control group (all p < 0.05).
Significantly more patients in the elderly group had
stage 3 or 4 chronic kidney disease than those in the
control group (p < 0.01). There were no between-
group differences in fasting plasma glucose, HbA1c,
bicarbonate, sodium, potassium, and chloride levels,
or anion gap. Furthermore, there was no between-
group difference in plasma lactate levels. There was
no relationship between lactate levels and metformin
dose (Figure 1).
The distribution of fasting plasma lactate levels for
all patients is shown in Figure 2. Twenty patients in
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the elderly group (33.3%) and 22 in the control group
(25.8%) had plasma lactate levels that were higher
than the normal upper limit of 15 mg/dL, which was
not statistically significant. None of the patients ful-
filled the lactic acidosis criteria indicated by anion gap
acidosis with a plasma lactate > 50 mg/dL.9
eCCr was negatively associated with plasma lactate
levels in elderly patients (Figure 3A, p < 0.05), but no
such association was found in the control group (data
not shown). When the data from all 145 patients were
combined, plasma glucose levels were positively cor-
related with fasting plasma lactate levels (Figure 3B,
p < 0.01).
Table 2 summarizes the characteristics of patients
with respect to those who did and those who did not
have hyperlactemia. Fasting plasma glucose levels
were significantly higher in hyperlactemic patients
(p = 0.01).
Multivariate logistic regression analysis revealed
that patients with a fasting plasma glucose level
> 130 mg/dL had a 2.8-fold risk of becoming hyper-
lactemic. Age, eCCr, BMI, metformin dose, HbA1c,
creatinine, sodium, and potassium levels were not risk
factors for hyperlactemia.
Discussion
Lactic acidosis is the most serious side effect of
biguanide therapy. Compared with phenformin, met-
formin does not affect lactate turnover,10,11 accumulate
in the mitochondria, inhibit the electron transport
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Table 1. Basic characteristics of the elderly and control groups*
Elderly group (n = 66) Control group (n = 79) p
Age (yr) 83.6 ± 2.8 59.6 ± 9.6
Sex (male/female) 56/23 52/14 0.37
Body mass index (kg/m2) 24.4 ± 3.2 26.3 ± 4.4 < 0.05
Fasting plasma glucose (mg/dL) 132.9 ± 29.7 139.4 ± 26.5 0.116
HbA1c (%) 6.9 ± 0.9 7.2 ± 1.2 0.108
eCCr (mL/min) 48.9 ± 12.9 80.3 ± 30.1 < 0.01
Metformin dose (mg/d) 1,408.3 ± 501.9 1,618.9 ± 522.8 < 0.05
Plasma lactate (mg/dL) 13.2 ± 5.2 13.5 ± 4.8 0.888
Bicarbonate (mmol/L) 27.63 ± 2.7 28.09 ± 3.2 0.237
Sodium (mmol/L) 140.7 ± 2.8 140.6 ± 2.3 0.724
Potassium (mmol/L) 4.4 ± 0.3 4.4 ± 0.5 0.749
Chloride (mmol/L) 104.1 ± 2.8 103.3 ± 2.7 0.114
Anion gap (mmol/L) 8.8 ± 3.1 9.2 ± 3.1 0.615
*Data are presented as mean ± standard deviation or n. HbA1c = glycated hemoglobin; eCCr = estimated creatinine clearance rate.
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Figure 1. Mean plasma lactate level at 3 different metformin
doses. There were no significant differences in fasting plasma
lactate level among the 3 metformin dose groups (Kruskal-Wallis
test, p = 0.327).
Figure 2. Distribution of fasting plasma lactate level in metformin-
treated patients. The dotted line indicates the normal upper limit
for plasma lactate levels.
chain,10 or increase lactate oxidation.11 Metformin is
not metabolized by the liver and is excreted mainly by
the kidneys. Therefore, the incidence of lactic acidosis
is much lower with metformin than phenformin 
therapy.
It has been reported that patients with type 2 dia-
betes taking metformin have higher plasma lactate lev-
els than those not taking metformin.12 Indeed, case
reports of metformin-associated lactic acidosis continue
to be published. In the present study, we found that a
fasting plasma glucose level in excess of 130 mg/dL
increased the risk of hyperlactemia 2.8-fold. The rea-
son for this increased risk is unclear; however, several
explanations have been proposed.12–15 It may be par-
tially explained by sympathetic overactivity related to
hyperglycemia, leading to increased plasma lactate
levels.12 Alternatively, decreased expression of acetyl-
CoA associated with metformin therapy may favor the
formation of lactate from glucose.15 However, it is
still unclear as to whether metformin treatment, in
the face of existing hyperglycemia, causes a synergistic
increase in plasma lactate levels and further increases
the risk of lactic acidosis.
There is controversy in the literature as to whether
or not old age is a risk factor for metformin-associated
lactic acidosis. In this study, we found that there was
no significant difference in plasma lactate levels between
elderly and comparatively younger patients. Our find-
ings are consistent with those reported by Gregorio
et al,16 who also failed to find higher plasma lactate
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Table 2. Characteristics of patients with and without hyperlactemia*
Plasma lactate > 15 mg/dL (n = 42) Plasma lactate ≤ 15 mg/dL (n = 103) p
Age (yr) 71.5 ± 14.6 (38–90) 70.3 ± 13.6 (37–90) 0.634
Sex (male/female) 34/8 74/29 0.352
Body mass index (kg/m2) 26.0 ± 3.5 (17.8–33.9) 25.2 ± 4.2 (17.6–36.3) 0.141
Fasting plasma glucose (mg/dL) 148.7 ± 32.1 (90–276) 131.4 ± 24.7 (90–276) 0.001
HbA1c (%) 7.3 ± 1.2 (5.3–12.2) 7.0 ± 1.1 (5.1–11.6) 0.144
Serum creatinine (mg/dL) 1.1 ± 0.4 (0.5–2.5) 1.0 ± 0.4 (0.4–2.9) 0.228
eCCr (mL/min) 64.0 ± 30.8 (24.9–129) 67.0 ± 27.8 (175–133) 0.498
CKD stages 3, 4 19 (48.7) 46 (50.0) 1
Metformin dose (mg/d) 1,590 ± 521.5 (500–2,550) 1,495.6 ± 522.7 (500–2,000) 0.262
Anion gap (mmol/L) 10.5 ± 3.4 (3.1–14.4) 8.4 ± 2.8 (1.5–12.3) 0.615
*Data are presented as mean ± standard deviation (range) or n or n (%). HbA1c = glycated hemoglobin; eCCr = estimated creatinine clearance rate; CKD =
chronic kidney disease.
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Figure 3. (A) Regression analysis demonstrating the relationship between plasma lactate levels and estimated creatinine clearance
rate (eCCr) in the elderly patient group. Lactate levels were negatively correlated with eCCr (r = −0.27; p = 0.029; n = 66). (B) Regression
analysis demonstrating the relationship between plasma lactate and fasting plasma glucose levels in all metformin-treated patients.
Lactate levels were positively correlated with plasma glucose levels (r = 0.23; p = 0.005; n = 145).
levels in elderly patients with diabetes receiving met-
formin monotherapy or add-on sulfonylurea therapy.
Mean daily metformin doses were significantly lower
in our elderly patient group than in the control group.
This difference may have been due to the prescribing
physician being overly concerned about potential side
effects, such as lactic acidosis or gastrointestinal dis-
comfort, in older patients. Nevertheless, we found no
significant differences in plasma lactate levels among
patients taking different doses of metformin. Davis 
et al12 and Lim et al17 also reported that plasma lactate
levels are not related to metformin dose.
In agreement with the findings from several previ-
ous clinical series,9,18 we did not encounter any cases
of lactic acidosis in elderly patients on metformin
therapy. In contrast, Khan et al19 reported 2 cases of
metformin-associated hyperlactemia in patients aged
82 and 76 years. In June 1996, 1 year after metformin
was approved for use in the USA, the Food and Drug
Administration received reports of 47 confirmed cases
of metformin-associated lactic acidosis. Among these,
8 patients (17%) were older than 80 years.7 The sub-
sequently revised label stated that metformin treatment
should not be initiated in patients ≥ 80 years old. 
In our series, fasting plasma lactate levels in elderly
metformin-treated patients with type 2 diabetes did
not differ from those in younger patients, despite the
finding that these patients had lower eCCr rates.
However, fasting plasma lactate levels were negatively
correlated with eCCr in the elderly patient group, but
not in the younger control group. Rachmani et al20
suggested that metformin is tolerable with mild renal
impairment, even when the creatinine level is
> 1.47 mg/dL. This may not have been the case in
our study, especially for the elderly group of patients.
It is important to be aware that creatinine levels often
overestimate renal function, particularly in the elderly.
Calculation of eCCr, not just creatinine monitoring,
is especially prudent in elderly patients in whom even
a minor elevation in creatinine levels (even within the
normal range) may be associated with accumulation of
lactate in the serum. Therefore, we suggest that met-
formin should be cautiously prescribed for patients
older than 80 years with mildly impaired renal function.
This study has several limitations. First, it was a
cross-sectional, but not prospective, study, in which
none of the patients developed lactic acidosis. We do
not know the evolution of these patients with mild
hyperlactemia. Second, the patients in this study were
ambulatory elderly patients; therefore, the findings may
not necessarily be applicable to the entire elderly pop-
ulation receiving metformin treatment for type 2 dia-
betes, many of whom undoubtedly have comorbidities.
In conclusion, our findings suggest that old age
per se should not preclude prescription of metformin
for treatment of type 2 diabetes. We found that fasting
plasma lactate levels in elderly patients with type 2
diabetes patients were not different from those in
control group patients, and none of them met the cri-
teria for diagnosis of lactic acidosis. However, met-
formin should still be cautiously prescribed, especially
in elderly diabetic patients with mild renal impairment,
and assessment of not only serum creatinine but also
eCCr is recommended in this population. Patients
with a fasting plasma glucose level > 130 mg/dL had
a 2.8-fold risk of developing hyperlactemia. The clini-
cal implication of this phenomenon remains uncertain.
Lactate measurement to assess incipient acidosis may
be helpful in such situations.
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